Berirab P

What is Berirab P?

Berirab P 300 IU/2 mL is a human rabies immunoglobulin used as part of post-exposure prophylaxis (PEP) for people who may have been exposed to rabies. The product contains human immunoglobulin antibodies with activity against the rabies virus. The pack shown contains a 2 mL prefilled syringe providing at least 300 IU of rabies antibodies. Product information identifies CSL Behring GmbH in Marburg, Germany, as the manufacturer.

Rabies is a serious viral infection that can affect the central nervous system. Once clinical symptoms develop, rabies is almost invariably fatal, which is why appropriate medical evaluation after a potentially risky animal exposure is extremely important.

Berirab P belongs to the class of specific human immunoglobulins. Unlike a vaccine, which stimulates the body’s immune system to develop its own longer-lasting immune response, rabies immunoglobulin supplies ready-made antibodies. This provides immediate passive immune protection during the early period following an exposure.

Berirab P is intended to be used together with an appropriate rabies vaccination regimen when indicated. It is not a substitute for rabies vaccination. Official product information specifically states that human rabies immunoglobulin should be used in combination with rabies vaccine.

Because rabies exposure can be a medical emergency, Berirab P should only be administered by an appropriately qualified healthcare professional following assessment of the exposure and applicable medical guidelines.

Uses of Berirab P

Berirab P is primarily used for post-exposure prophylaxis of rabies following potentially significant exposure to the virus.

Medically recognized uses include:

• Post-exposure prophylaxis following bites from an animal suspected of having rabies.
• Protection following scratches or other injuries caused by a potentially rabid animal.
• Use following contamination of mucous membranes with saliva or infectious tissue from a suspected rabid animal.
• Use in certain circumstances involving exposure to rabies-containing live attenuated vaccine material, as described in product information.

The need for rabies immunoglobulin depends on the type and circumstances of exposure, vaccination history, and applicable public-health recommendations. Wound care and rabies vaccination are also important components of post-exposure management.

Berirab P should only be used under the supervision of a qualified healthcare professional.

Benefits of Berirab P

When clinically indicated, Berirab P can provide important benefits as part of rabies post-exposure prophylaxis.

Potential benefits include:

• Provides passive antibodies against rabies virus.
• Offers immediate antibody-mediated protection while the immune response to rabies vaccination develops.
• Supports comprehensive post-exposure management after qualifying animal exposures.
• Can help provide local antibody activity when appropriately administered as part of professional wound management.
• Complements rabies vaccination rather than replacing it.
• Can be an important component of treatment following potentially serious rabies exposure.

The purpose of Berirab P is prevention after exposure; it should not be described as a treatment that cures established symptomatic rabies.

How Does Berirab P Work?

Berirab P contains human antibodies directed against the rabies virus. These antibodies are obtained from human plasma and provide passive immunity.

Following a qualifying exposure, the rabies virus may initially be present at or near the exposure site before progressing through the body. Rabies immunoglobulin provides ready-made antibodies that can help neutralize rabies virus during this early period.

Rabies vaccination works differently. The vaccine stimulates the person’s own immune system to produce an active immune response. The immunoglobulin provides immediate passive antibodies, while vaccination develops the longer-term immune response.

For this reason, when rabies immunoglobulin is indicated, it is used as part of a complete post-exposure prophylaxis program rather than as an alternative to vaccination.

How to Take Berirab P

Berirab P is a prescription biological medicine administered by a healthcare professional. It is not intended for self-administration.

Important points include:

• Use only when recommended by a qualified healthcare professional.
• The healthcare professional determines the appropriate treatment according to the exposure and applicable rabies-prophylaxis guidelines.
• It is administered through an appropriate injection route by trained medical personnel.
• The immunoglobulin and rabies vaccine are administered at separate anatomical sites when used together.
• Patients should follow the complete rabies vaccination plan recommended by their healthcare provider.
• Do not attempt to administer or adjust this medicine without professional supervision.

The official product information emphasizes that rabies immunoglobulin and the first rabies vaccine dose should be given as soon as possible when indicated after exposure.

Berirab P Side Effects

Like all medicines, Berirab P may cause side effects, although not everyone experiences them.

Common or Less Serious Effects

Possible reactions can include:

• Pain or tenderness at the injection site
• Swelling at the injection site
• Local discomfort or irritation

These reactions are generally temporary, but patients should tell their healthcare provider if they are persistent or troublesome.

Serious Side Effects

Rare but potentially serious reactions can include:

• Severe allergic or hypersensitivity reactions
• Difficulty breathing
• Significant fall in blood pressure
• Anaphylactic reaction or shock

The product information notes that severe hypersensitivity reactions can occur rarely, including in individuals who have previously tolerated immunoglobulin products.

Medical observation after administration may therefore be appropriate, particularly when there is concern about an allergic reaction.

If side effects persist or become severe, contact your healthcare provider promptly.

Warnings and Precautions

Berirab P should be used with appropriate medical supervision.

Allergies

Patients should tell their healthcare professional about previous allergic reactions to human immunoglobulin products or blood-derived medicines. Individuals with certain immunoglobulin A (IgA) deficiencies may have a higher risk of serious hypersensitivity reactions.

Pregnancy and Breastfeeding

Available clinical experience with immunoglobulins is reassuring, but the decision to use Berirab P during pregnancy or breastfeeding should be made by a healthcare professional after considering the potential benefits and risks.

Kidney or Liver Problems

Patients with significant kidney or liver conditions should inform their healthcare provider before receiving treatment. The clinician can determine appropriate management based on the person’s overall condition.

Bleeding Disorders

Because the product is normally administered by injection, patients with coagulation disorders or conditions that increase bleeding risk should inform the treating healthcare professional.

Driving and Machinery

The product information reports that no effects on the ability to drive or operate machinery have been observed. However, anyone experiencing dizziness, weakness, or an allergic reaction should seek medical advice before driving.

Drug Interactions

Berirab P can interact with certain medical treatments, particularly some live attenuated virus vaccines. Immunoglobulin administration may temporarily reduce the effectiveness of certain live vaccines, including measles, mumps, rubella, and varicella vaccines. The appropriate timing should therefore be assessed by a healthcare professional.

Before receiving Berirab P, tell your doctor about:

• Prescription medicines
• Over-the-counter medicines
• Vaccines received recently
• Vitamins and nutritional products
• Herbal or complementary medicines
• Previous immunoglobulin treatment

Do not stop or change another medicine without professional advice.

Storage Instructions

Berirab P requires appropriate temperature-controlled storage.

According to product information:

• Store at 2°C to 8°C.
• Do not freeze.
• Keep the product in its original outer carton to protect it from light.
• Keep out of the reach and sight of children.
• Do not use after the expiry date.
• Do not use the solution if it appears unsuitable or contains visible deposits or particles.
• Once the container has been opened, the contents should be used immediately according to professional handling requirements.

Healthcare facilities should follow the manufacturer’s storage and handling requirements.

Berirab P Price and Availability

The Berirab P price can vary according to country, supplier, taxes, import requirements, and local availability. Because Berirab P is a specialized biological medicine used for rabies post-exposure prophylaxis, availability may also differ between healthcare facilities and regions.

For safety reasons, patients should obtain this medicine only through legitimate healthcare channels and use it strictly under professional supervision. Product availability and pricing should be confirmed through an authorized pharmacy, hospital, or healthcare provider rather than relying on unverified sources.

Berirab P Manufacturer

Berirab P manufacturer: CSL Behring GmbH
Manufacturer location: Emil-von-Behring-Strasse 76, 35041 Marburg, Germany.

CSL Behring is a global biopharmaceutical company involved in the development and manufacture of plasma-derived and recombinant medicines. Official product and medical information should be consulted when specific questions about the product arise.

Frequently Asked Questions

1. What is Berirab P used for?

Berirab P is a human rabies immunoglobulin used as part of post-exposure prophylaxis following certain potentially dangerous exposures to rabies, such as bites or scratches from an animal suspected of having rabies. When indicated, it is used together with an appropriate rabies vaccination regimen.

2. How does Berirab P work?

Berirab P provides ready-made human antibodies against rabies virus. These antibodies provide passive immune protection during the early period following exposure while the person’s immune response to rabies vaccination develops.

3. Is Berirab P safe?

Berirab P is an established human rabies immunoglobulin product, but like other biological medicines, it can cause adverse reactions. Allergic reactions are uncommon but can occasionally be serious. It should therefore be administered under qualified medical supervision.

4. Can Berirab P be used without rabies vaccine?

Berirab P is not intended to replace rabies vaccination. When rabies immunoglobulin is indicated for post-exposure prophylaxis, it is used in combination with rabies vaccine according to applicable medical guidelines.

5. What are the common Berirab P side effects?

Possible side effects include local pain, tenderness, or swelling at the injection site. Rarely, allergic reactions can occur. Severe symptoms such as breathing difficulty or a major allergic reaction require immediate medical attention.

6. Who should tell their doctor before receiving Berirab P?

Anyone with a history of serious allergic reactions to immunoglobulin products, known IgA deficiency, bleeding or coagulation problems, pregnancy, breastfeeding, or significant medical conditions should inform their healthcare provider before treatment.

7. Can Berirab P interact with vaccines?

Yes. Human immunoglobulins may interfere with certain live attenuated vaccines. The timing of vaccines such as measles, mumps, rubella, and varicella vaccines may need professional assessment.

8. How should Berirab P be stored?

Berirab P should be refrigerated at 2°C to 8°C, protected from light, and should not be frozen. It should remain in its original carton until required for use.

9. Can Berirab P be used for every animal bite?

No. The need for rabies immunoglobulin depends on the nature of the exposure, the animal involved, vaccination history, and medical/public-health guidance. Anyone with a potentially significant rabies exposure should receive prompt professional medical assessment.

10. Is Berirab P a cure for rabies?

No. Berirab P is used for post-exposure prevention and is not a cure for symptomatic rabies. Prompt medical assessment, wound management, and appropriate rabies vaccination are essential after a potentially significant exposure.

Disclaimer

This information about Berirab P 300 IU/2 mL is provided for educational and informational purposes only and should not be considered medical advice. It does not replace consultation with a qualified doctor, pharmacist, or other healthcare professional.

Berirab P is a specialized biological medicine that should only be used when medically indicated and administered under appropriate professional supervision. Do not self-medicate, alter treatment, or delay medical care after a potentially significant rabies exposure. Individual treatment decisions depend on the exposure, vaccination history, medical condition, and applicable clinical guidelines.

For the most accurate and current information, healthcare professionals should consult the approved product information and relevant national or international rabies-prophylaxis recommendations.